Fig. 6
From: A novel in vitro model for the assessment of postnatal myonuclear accretion
Myomaker is specifically required in myoblasts for in vitro postnatal myonuclear accretion in C2C12 cells. Luciferase-based assessment of myonuclear accretion 3 days after initiation of co-culturing of myotubes (MT) with myoblasts (MB) which received 24-h pre-treatment with either negative control siRNA (siNeg) or siRNA against Myomaker (siMyo) (n = 4). a Luciferase activity (RLU) per well, b protein content (μg/μL) per well, c relative luciferase activity (RLU/protein content) per well. Parallel experiment of siRNA treated MT and MB, maintained in separate cultures. d Western blot of Myomaker, e densitometric analysis of 20 kDa band (n = 8). Values are means ± SEM. ***p < 0.001 compared to control